Heart failure & cardiomyopathiesSecondary analysis
Recurrent Hospitalizations and Response to Vericiguat in Heart Failure and Reduced Ejection Fraction
- Secondary analysis of the VICTORIA randomised trial
- recurrent event analysis (Andersen-Gill)
Authors' conclusion
Additional investigation of the association between vericiguat and cardiovascular death and total HF hospitalizations by recurrent event analysis did not show a statistically significant reduction in events. Mortality was high after HF hospitalization
Study context
- Population
- Patients with HFrEF in the VICTORIA trial
- Participants
- 2,526 vs 2,524
- Comparison
- Vericiguat vs placebo
- Vericiguatn = 2,526
- Placebon = 2,524reference
- Primary endpoint
- Total HF hospitalizations and CV death (recurrent events)
Primary result
As reported in the abstract
Total HF hospitalizations and CV deaths
Vericiguat
1,222
events
Placebo
1,336
events
Vericiguat vs PlaceboHazard ratio (95% CI)
unadjusted
0.89(0.81–0.97)
adjusted for VICTORIA model covariates
0.92(0.84–1.01)
Further findings
| Outcome | adjusted HR (95% CI) | |
|---|---|---|
| Total HF hospitalizations and CV deaths, by baseline NT-proBNP quartile (subgroup) · Q1 | 0.80 (0.64–1.01) | |
| Total HF hospitalizations and CV deaths, by baseline NT-proBNP quartile (subgroup) · Q2 | 0.77 (0.62–0.94) | |
| Total HF hospitalizations and CV deaths, by baseline NT-proBNP quartile (subgroup) · Q3 | 1.12 (0.93–1.34) | |
| Total HF hospitalizations and CV deaths, by baseline NT-proBNP quartile (subgroup) · Q4 | 0.87 (0.74–1.04) | |
| 0.512Adjusted hazard ratio (log scale) |
All-cause mortality after HF hospitalization (events per 100 patient-years)
Total heart failure (HF) hospitalizations and CV deaths, by baseline NT-proBNP quartile (subgroup)
- Suggestion of benefit with NT-proBNP ≤2,816 pg/mL (Q1 and Q2)
Treatment effect by prior HF hospitalization
- No significant difference in treatment effect between patients with vs without an HF hospitalization
Original publication
Recurrent Hospitalizations and Response to Vericiguat in Heart Failure and Reduced Ejection Fraction. JACC Heart Fail. Published 14 February 2024. doi:10.1016/j.jchf.2023.12.005
Summarised from the published abstract; every number is checked against it